Daewoong Co., Ltd. (KRX:003090)
16,610
-1,240 (-6.95%)
Jun 8, 2026, 3:30 PM KST
Daewoong Revenue
Daewoong had revenue of 492.71B KRW in the quarter ending March 31, 2026, with 2.34% growth. This brings the company's revenue in the last twelve months to 2.08T, up 5.33% year-over-year. In the year 2025, Daewoong had annual revenue of 2.07T with 6.79% growth.
Revenue (ttm)
2.08T
Revenue Growth
+5.33%
P/S Ratio
0.35
Revenue / Employee
5.49B
Employees
379
Market Cap
729.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.07T | 131.45B | 6.79% |
| Dec 31, 2024 | 1.94T | 123.08B | 6.79% |
| Dec 31, 2023 | 1.81T | 116.50B | 6.86% |
| Dec 31, 2022 | 1.70T | 185.96B | 12.30% |
| Dec 31, 2021 | 1.51T | 156.04B | 11.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Pharmaceutical | 1.74T |
| Daewoong Pharmaceutical | 1.59T |
| Dong-A Socio Holdings | 1.45T |
| Boryung | 1.03T |
| DongKook Pharmaceutical | 954.16B |
| Dong-A ST | 830.27B |
| JW Pharmaceutical | 789.95B |
| Ildong Pharmaceutical | 572.95B |
Daewoong News
- 4 months ago - AEON Biopharma Completes BPD Type 2a Meeting With FDA - Nasdaq